enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Direct factor Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Direct_factor_Xa_inhibitors

   Compared to the risk of bleeding with warfarin use, direct factor Xa inhibitors have a higher risk of GI bleeding, but lower risk of bleeding in the brain. [2] Other side effects may include stomach upset, dizziness, anemia or increased blood levels of liver enzymes. [2]

3. Discovery and development of direct Xa inhibitors - Wikipedia

   en.wikipedia.org/wiki/Discovery_and_development...

   Rivaroxaban (Xarelto) was the first approved FXa inhibitor to become commercially available in Europe and Canada in 2008. [1] The second one was apixaban (Eliquis), approved in Europe in 2011 [2] and in the United States in 2012. [3] The third one edoxaban (Lixiana, Savaysa) was approved in Japan in 2011 and in Europe and the US in 2015. [4]

4. Dabigatran - Wikipedia

   en.wikipedia.org/wiki/Dabigatran

   The safety and efficacy of Pradaxa (dabigatran) were evaluated in the European RE-ALIGN trial in 2012. RE-ALIGN was terminated early because the Pradaxa treatment group had significantly more thromboembolic events and major bleeding than warfarin and determined to be contraindicated for use in patients with mechanical heart valves. [20]

5. Subanalysis of Phase III ARISTOTLE Trial of Eliquis ... - AOL

   www.aol.com/news/2013-09-03-subanalysis-of-phase...

   Subanalysis of Phase III ARISTOTLE Trial of Eliquis® (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart ...

6. Direct thrombin inhibitor - Wikipedia

   en.wikipedia.org/wiki/Direct_thrombin_inhibitor

   Dabigatran is an oral direct thrombin inhibitor. Dabigatran (Pradaxa) was found to be noninferior to Warfarin in prevention of ischemic stroke, as well as intracranial hemorrhage risk and overall mortality for non-valvular atrial fibrillation according to the RE-LY trial. [9]

7. Sales of Pfizer Inc. and Bristol-Myers Squibb Co.'s Eliquis ...

   www.aol.com/news/2014-01-27-sales-of-pfizer-inc...

   A new class of blood-thinning drugs is winning market share from decades-old warfarin, a commonly prescribed drug used to reduce blood clots in patients with heart disease or that have undergone ...

8. Apixaban - Wikipedia

   en.wikipedia.org/wiki/Apixaban

   Compared to warfarin it has fewer interactions with other medications. [10] It is a direct factor Xa inhibitor. [6] In 2007, Pfizer and Bristol-Myers Squibb began the development of apixaban as an anticoagulant. [11] Apixaban was approved for medical use in the European Union in May 2011, and in the United States in December 2012.

9. J&J Wins Blockbuster Approval to Market Xarelto for Stroke ...

   www.aol.com/news/2011-11-05-jj-wins-blockbuster...

   For premium support please call: 800-290-4726 more ways to reach us